-
1
-
-
0002557986
-
Human serum paraoxonase/arylesterase
-
W. Kalow Pergamon New York, NY
-
B.N. La Du Human serum paraoxonase/arylesterase W. Kalow Pharmacogenetics of drug metabolism 1992 Pergamon New York, NY 51 91
-
(1992)
Pharmacogenetics of Drug Metabolism
, pp. 51-91
-
-
La Du, B.N.1
-
2
-
-
0027412483
-
Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase
-
M.C. Blatter, R.W. James, and S. Messmer Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase Eur. J. Biochem. 211 1993 871 879
-
(1993)
Eur. J. Biochem.
, vol.211
, pp. 871-879
-
-
Blatter, M.C.1
James, R.W.2
Messmer, S.3
-
3
-
-
0025864611
-
Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein
-
M.I. Mackness, S. Arrol, and P.N. Durrington Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein FEBS Lett. 286 1991 152 154
-
(1991)
FEBS Lett.
, vol.286
, pp. 152-154
-
-
MacKness, M.I.1
Arrol, S.2
Durrington, P.N.3
-
4
-
-
0027763632
-
Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
-
M.I. Mackness, S. Arrol, and C. Abbott Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase Atherosclerosis 104 1993 129 135
-
(1993)
Atherosclerosis
, vol.104
, pp. 129-135
-
-
MacKness, M.I.1
Arrol, S.2
Abbott, C.3
-
5
-
-
0032522985
-
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase
-
M. Aviram, M. Rosenblat, and C.L. Bisgaier Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase J. Clin. Invest. 101 1998 1581 1590
-
(1998)
J. Clin. Invest.
, vol.101
, pp. 1581-1590
-
-
Aviram, M.1
Rosenblat, M.2
Bisgaier, C.L.3
-
6
-
-
0035574446
-
Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype?
-
B. Mackness, G.K. Davies, and W. Turkie Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 21 2001 1451 1457
-
(2001)
Arterioscler. Thromb. Vasc. Biol.
, vol.21
, pp. 1451-1457
-
-
MacKness, B.1
Davies, G.K.2
Turkie, W.3
-
7
-
-
0032537833
-
Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
-
D.M. Shih, L. Gu, and Y.R. Xia Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis Nature 394 1998 284 287
-
(1998)
Nature
, vol.394
, pp. 284-287
-
-
Shih, D.M.1
Gu, L.2
Xia, Y.R.3
-
8
-
-
0037162376
-
Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice
-
A. Tward, Y.R. Xia, and X.P. Wang Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice Circulation 106 2002 484 490
-
(2002)
Circulation
, vol.106
, pp. 484-490
-
-
Tward, A.1
Xia, Y.R.2
Wang, X.P.3
-
9
-
-
0027396833
-
The molecular basis of the human serum paraoxonase activity polymorphism
-
R. Humbert, D.A. Adler, and C.M. Disteche The molecular basis of the human serum paraoxonase activity polymorphism Nat. Genet. 3 1993 73 76
-
(1993)
Nat. Genet.
, vol.3
, pp. 73-76
-
-
Humbert, R.1
Adler, D.A.2
Disteche, C.M.3
-
10
-
-
0029118601
-
Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
-
J. Ruiz, H. Blanche, and R.W. James Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes Lancet 346 1995 869 872
-
(1995)
Lancet
, vol.346
, pp. 869-872
-
-
Ruiz, J.1
Blanche, H.2
James, R.W.3
-
11
-
-
0028809494
-
A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease
-
M. Serrato, and A.J. Marian A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease J. Clin. Invest. 96 1995 3005 3008
-
(1995)
J. Clin. Invest.
, vol.96
, pp. 3005-3008
-
-
Serrato, M.1
Marian, A.J.2
-
12
-
-
0002198623
-
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes
-
M.C. Garin, R.W. James, and P. Dussoix Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes J. Clin. Invest. 99 1997 62 66
-
(1997)
J. Clin. Invest.
, vol.99
, pp. 62-66
-
-
Garin, M.C.1
James, R.W.2
Dussoix, P.3
-
13
-
-
0029788728
-
The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns
-
M. Antikainen, S. Murtomaki, and M. Syvanne The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns J. Clin. Invest. 98 1996 883 885
-
(1996)
J. Clin. Invest.
, vol.98
, pp. 883-885
-
-
Antikainen, M.1
Murtomaki, S.2
Syvanne, M.3
-
14
-
-
0030589165
-
Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease
-
T. Suehiro, Y. Nakauchi, and M. Yamamoto Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease Int. J. Cardiol. 57 1996 69 73
-
(1996)
Int. J. Cardiol.
, vol.57
, pp. 69-73
-
-
Suehiro, T.1
Nakauchi, Y.2
Yamamoto, M.3
-
15
-
-
0034111840
-
A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression
-
T. Suehiro, T. Nakamura, and M. Inoue A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression Atherosclerosis 150 2000 295 298
-
(2000)
Atherosclerosis
, vol.150
, pp. 295-298
-
-
Suehiro, T.1
Nakamura, T.2
Inoue, M.3
-
16
-
-
0033973018
-
Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations
-
I. Leviev, and R.W. James Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations Arterioscler. Thromb. Vasc. Biol. 20 2000 516 521
-
(2000)
Arterioscler. Thromb. Vasc. Biol.
, vol.20
, pp. 516-521
-
-
Leviev, I.1
James, R.W.2
-
18
-
-
0031921406
-
Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus
-
Y. Ikeda, T. Suehiro, and M. Inoue Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus Metabolism 47 1998 598 602
-
(1998)
Metabolism
, vol.47
, pp. 598-602
-
-
Ikeda, Y.1
Suehiro, T.2
Inoue, M.3
-
19
-
-
0033756537
-
Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes
-
M. Inoue, T. Suehiro, and T. Nakamura Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes Metabolism 49 2000 1400 1405
-
(2000)
Metabolism
, vol.49
, pp. 1400-1405
-
-
Inoue, M.1
Suehiro, T.2
Nakamura, T.3
-
20
-
-
0032554676
-
Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
-
WOSCOP study group
-
WOSCOP study group Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) Circulation 97 1998 1440 1445
-
(1998)
Circulation
, vol.97
, pp. 1440-1445
-
-
-
21
-
-
0034053890
-
Non-lipid-related effects of statins
-
S. Bellosta, N. Ferri, and F. Bernini Non-lipid-related effects of statins Ann. Med. 32 2000 164 176
-
(2000)
Ann. Med.
, vol.32
, pp. 164-176
-
-
Bellosta, S.1
Ferri, N.2
Bernini, F.3
-
22
-
-
0027492038
-
Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages
-
L.M. Giroux, J. Davignon, and M. Naruszewicz Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages Biochim. Biophys. Acta 1165 1993 335 338
-
(1993)
Biochim. Biophys. Acta
, vol.1165
, pp. 335-338
-
-
Giroux, L.M.1
Davignon, J.2
Naruszewicz, M.3
-
23
-
-
0032103277
-
Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
-
M. Aviram, M. Rosenblat, and C.L. Bisgaier Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation Atherosclerosis 138 1998 271 280
-
(1998)
Atherosclerosis
, vol.138
, pp. 271-280
-
-
Aviram, M.1
Rosenblat, M.2
Bisgaier, C.L.3
-
24
-
-
0033817620
-
Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients
-
M. Tomas, M. Senti, and F. Garcia-Faria Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients Arterioscler. Thromb. Vasc. Biol. 20 2000 2113 2119
-
(2000)
Arterioscler. Thromb. Vasc. Biol.
, vol.20
, pp. 2113-2119
-
-
Tomas, M.1
Senti, M.2
Garcia-Faria, F.3
-
25
-
-
0141456209
-
Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6
-
Y. Kumon, T. Suehiro, and Y. Ikeda Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6 Life Sci. 73 2003 2807 2815
-
(2003)
Life Sci.
, vol.73
, pp. 2807-2815
-
-
Kumon, Y.1
Suehiro, T.2
Ikeda, Y.3
-
26
-
-
0034534465
-
Heterogeneous Sp1 mRNAs in human HepG2 cells include a product of homotypic trans-splicing
-
T. Takahara, S.I. Kanazu, and S. Yanagisawa Heterogeneous Sp1 mRNAs in human HepG2 cells include a product of homotypic trans-splicing J. Biol. Chem. 275 2000 38067 38072
-
(2000)
J. Biol. Chem.
, vol.275
, pp. 38067-38072
-
-
Takahara, T.1
Kanazu, S.I.2
Yanagisawa, S.3
-
27
-
-
0034994075
-
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I
-
G. Martin, H. Duez, and C. Blanquart Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I J. Clin. Invest. 107 2001 1423 1432
-
(2001)
J. Clin. Invest.
, vol.107
, pp. 1423-1432
-
-
Martin, G.1
Duez, H.2
Blanquart, C.3
-
28
-
-
0033618378
-
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)
-
U. Laufs, D. Marra, and K. Node 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1) J. Biol. Chem. 274 1999 21926 21931
-
(1999)
J. Biol. Chem.
, vol.274
, pp. 21926-21931
-
-
Laufs, U.1
Marra, D.2
Node, K.3
-
29
-
-
0032487342
-
3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins
-
M. Essig, G. Nguyen, and D. Prie 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins Circ. Res. 83 1998 683 690
-
(1998)
Circ. Res.
, vol.83
, pp. 683-690
-
-
Essig, M.1
Nguyen, G.2
Prie, D.3
-
30
-
-
0026063559
-
The COOH-terminal domain of the Rap1A (Krev-1) protein is isoprenylated and supports transformation by an H-Ras:Rap1A chimeric protein
-
J.E. Buss, L.A. Quilliam, and K. Kato The COOH-terminal domain of the Rap1A (Krev-1) protein is isoprenylated and supports transformation by an H-Ras:Rap1A chimeric protein Mol. Cell. Biol. 11 1991 1523 1530
-
(1991)
Mol. Cell. Biol.
, vol.11
, pp. 1523-1530
-
-
Buss, J.E.1
Quilliam, L.A.2
Kato, K.3
-
32
-
-
0035957682
-
Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: Contribution to its anti-angiogenic effect
-
L. Vincent, W. Chen, and L. Hong Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect FEBS Lett. 495 2001 159 166
-
(2001)
FEBS Lett.
, vol.495
, pp. 159-166
-
-
Vincent, L.1
Chen, W.2
Hong, L.3
-
33
-
-
0037155865
-
Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB
-
S.A. Holstein, C.L. Wohlford-Lenane, and R.J. Hohl Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, AND RhoB J. Biol. Chem. 277 2002 10678 10682
-
(2002)
J. Biol. Chem.
, vol.277
, pp. 10678-10682
-
-
Holstein, S.A.1
Wohlford-Lenane, C.L.2
Hohl, R.J.3
-
34
-
-
0037137175
-
Isoprenoids influence expression of Ras and Ras-related proteins
-
S.A. Holstein, C.L. Wohlford-Lenane, and R.J. Hohl Isoprenoids influence expression of Ras and Ras-related proteins Biochemistry 41 2002 13698 13704
-
(2002)
Biochemistry
, vol.41
, pp. 13698-13704
-
-
Holstein, S.A.1
Wohlford-Lenane, C.L.2
Hohl, R.J.3
-
35
-
-
0030749232
-
Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism
-
J.A. Cuthbert, and P.E. Lipsky Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism Cancer Res. 57 1997 3498 3505
-
(1997)
Cancer Res.
, vol.57
, pp. 3498-3505
-
-
Cuthbert, J.A.1
Lipsky, P.E.2
-
36
-
-
0242721909
-
Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: A role for sterol regulatory element-binding protein-2
-
S. Deakin, I. Leviev, and S. Guernier Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2 Arterioscler. Thromb. Vasc. Biol. 23 2003 2083 2089
-
(2003)
Arterioscler. Thromb. Vasc. Biol.
, vol.23
, pp. 2083-2089
-
-
Deakin, S.1
Leviev, I.2
Guernier, S.3
-
37
-
-
0032921557
-
Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants
-
M. Aviram, M. Rosenblat, and S. Billecke Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants Free Radic. Biol. Med. 26 1999 892 904
-
(1999)
Free Radic. Biol. Med.
, vol.26
, pp. 892-904
-
-
Aviram, M.1
Rosenblat, M.2
Billecke, S.3
-
38
-
-
0033002575
-
Simvastatin decreases aldehyde production derived from lipoprotein oxidation
-
J. Girona, A.E. La Ville, and R. Sola Simvastatin decreases aldehyde production derived from lipoprotein oxidation Am. J. Cardiol. 83 1999 846 851
-
(1999)
Am. J. Cardiol.
, vol.83
, pp. 846-851
-
-
Girona, J.1
La Ville, A.E.2
Sola, R.3
|